MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31.

Income Overview

Net Income
-$236,990K
EPS
-$1.45
Unit: Thousand (K) dollars

Income Statement
2025-12-31
Research and development
176,065
General and administrative
60,091
Acquired in-process research and development
5,000
Total operating expenses
241,156
Loss from operations
-241,156
Interest income
8,344
Interest expense
3,219
Other expense, net
-767
Total other income
4,358
Net loss before income taxes
-236,798
Provision for income taxes
130
Net loss
-236,928
Unrealized gain (loss) on marketable securities
-62
Comprehensive loss
-236,990
Basic EPS
-1.45
Diluted EPS
-1.45
Basic Average Shares
163,391,000
Diluted Average Shares
163,391,000
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive loss-$236,990K Net loss-$236,928K Unrealized gain (loss) onmarketable securities-$62K Interest income$8,344K Net loss beforeincome taxes-$236,798K Provision for income taxes$130K Total other income$4,358K Interest expense$3,219K Other expense, net-$767K Loss from operations-$241,156K Total operatingexpenses$241,156K Research and development$176,065K General andadministrative$60,091K Acquired in-processresearch and development$5,000K

Neumora Therapeutics, Inc. (NMRA)

Neumora Therapeutics, Inc. (NMRA)